Nikkei Asian ReviewJapan firms to mass-produce blood-clotting treatment from stem cellsNikkei Asian ReviewTOKYO — Sixteen Japanese companies will spearhead an effort to develop a way to mass-produce from stem cells a blood component necessary for clot… Continue reading
Telegraph.co.uk |
Leading US biotech Bluebird eyes UK launch for pioneering gene therapies
Telegraph.co.uk One of America’s leading biotechs, Bluebird Bio, is in talks with UK medicine regulators about a potential launch of its pioneering range of gene therapies for rare diseases. Bluebird has a market value of over $4bn (£3bn) on New York’s Nasdaq stock … |
Singularity Hub |
Breakthrough Stem Cell Study Offers New Clues to Reversing Aging
Singularity Hub However, when the team transplanted these stem cells from young animals into a middle-aged one, they slowed aging. The recipient mice were smarter, more sociable and had better muscle function. And—get this—they also lived 10 to 15 percent longer … |
Tech Times |
Scientists Successfully Use CRISPR-Edited Skin Grafts To Treat Type-2 Diabetes And Obesity
Tech Times In order to prove this, the team used CRISPR to engineer mouse skin cell grafts that would regulate blood-glucose hormones when applied to diabetic mice with healthy immune systems. The patch carried a mutated gene that extends GLP-1’s half-life and … |
USA TODAY |
A clinical trial saved my life. It could save yours, too.
USA TODAY As I began my trial two years ago, immunotherapy — how I was treated — was almost completely unknown to the general public. But while I was on my trial, five immunotherapy drugs were approved for the treatment of eight different types of cancer … |
Minneapolis Star Tribune |
University of Minnesota bioethicist takes on clinics touting stem–cell studies
Minneapolis Star Tribune Listed on a government website, they present the opportunity to participate in clinical trials to test the potential of one of the most promising tools in medicine — the body’s own stem cells. It’s an attractive pitch for many patients, even though … |